{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:31:39Z","timestamp":1794047499262,"version":"4.8.0"},"reference-count":88,"publisher":"Ferrata Storti Foundation (Haematologica)","issue":"9","license":[{"start":{"date-parts":[[2025,4,10]],"date-time":"2025-04-10T00:00:00Z","timestamp":1744243200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["haematol"],"abstract":"<jats:p>Chromosomal translocation of the KMT2A gene represents the cytogenetic hallmark of acute lymphoblastic leukemia diagnosed in infants (&lt;1 year of age), driving a highly aggressive malignancy. For decades the event-free survival rates for these very young patients were at best ~40%. However, recent advances adding immunotherapy in the form of the bi-specific T-cell engager blinatumomab to the treatment led to encouraging results. In the present review we describe the current progress made, as well as the challenges that still lie ahead in terms of drug-related toxicity, the implementation of less toxic agents, acquired drug resistance, central nervous system involvement, and lineage switches. In addition, we touch on the benefit of preclinical models that can assist in guiding new treatment strategies.<\/jats:p>","DOI":"10.3324\/haematol.2024.285642","type":"journal-article","created":{"date-parts":[[2025,4,10]],"date-time":"2025-04-10T05:14:55Z","timestamp":1744262095000},"page":"1951-1961","source":"Crossref","is-referenced-by-count":11,"title":["&lt;I&gt;KMT2A&lt;\/i&gt;-rearranged acute lymphoblastic leukemia in infants: current progress and challenges"],"prefix":"10.3324","volume":"110","author":[{"given":"Janine","family":"Stutterheim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inge M.","family":"Van der Sluis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirsten S.","family":"Vrenken","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rob","family":"Pieters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald W.","family":"Stam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1856","published-online":{"date-parts":[[2025,4,10]]},"reference":[{"key":"79423","doi-asserted-by":"crossref","unstructured":"Pieters R, Schrappe M, De Lorenzo P. A treatment protocol for infants younger than 1 year with acute lymphoblastic leukaemia (Interfant-99): an observational study and a multicentre randomised trial. Lancet. 2007; 370(9583):240-250.","DOI":"10.1016\/S0140-6736(07)61126-X"},{"key":"79424","doi-asserted-by":"crossref","unstructured":"Pieters R, De Lorenzo P, Ancliffe P. Outcome of infants younger than 1 year with acute lymphoblastic leukemia treated with the Interfant-06 protocol: results from an international phase III randomized study. J Clin Oncol. 2019; 37(25):2246-2256.","DOI":"10.1200\/JCO.19.00261"},{"key":"79425","doi-asserted-by":"crossref","unstructured":"Meyer C, Larghero P, Almeida Lopes B. The KMT2A recombinome of acute leukemias in 2023. Leukemia. 2023; 37(5):988-1005.","DOI":"10.1038\/s41375-023-01877-1"},{"key":"79426","doi-asserted-by":"crossref","unstructured":"Meyer C, Burmeister T, Groger D. The MLL recombinome of acute leukemias in 2017. Leukemia. 2018; 32(2):273-284.","DOI":"10.1038\/leu.2017.213"},{"key":"79427","doi-asserted-by":"crossref","unstructured":"Murai MJ, Chruszcz M, Reddy G, Grembecka J, Cierpicki T. Crystal structure of menin reveals binding site for mixed lineage leukemia (MLL) protein. J Biol Chem. 2011; 286(36):31742-31748.","DOI":"10.1074\/jbc.M111.258186"},{"key":"79428","doi-asserted-by":"crossref","unstructured":"Yokoyama A, Cleary ML. Menin critically links MLL proteins with LEDGF on cancer-associated target genes. Cancer Cell. 2008; 14(1):36-46.","DOI":"10.1016\/j.ccr.2008.05.003"},{"key":"79429","doi-asserted-by":"crossref","unstructured":"Bernt KM, Zhu N, Sinha AU. MLL-rearranged leukemia is dependent on aberrant H3K79 methylation by DOT1L. Cancer Cell. 2011; 20(1):66-78.","DOI":"10.1016\/j.ccr.2011.06.010"},{"key":"79430","doi-asserted-by":"crossref","unstructured":"Okada Y, Feng Q, Lin Y. hDOT1L links histone methylation to leukemogenesis. Cell. 2005; 121(2):167-178.","DOI":"10.1016\/j.cell.2005.02.020"},{"key":"79431","doi-asserted-by":"crossref","unstructured":"Krivtsov AV, Feng Z, Lemieux ME. H3K79 methylation profiles define murine and human MLL-AF4 leukemias. Cancer Cell. 2008; 14(5):355-368.","DOI":"10.1016\/j.ccr.2008.10.001"},{"key":"79432","doi-asserted-by":"crossref","unstructured":"Dafflon C, Craig VJ, Mereau H. Complementary activities of DOT1L and menin inhibitors in MLL-rearranged leukemia. Leukemia. 2017; 31(6):1269-1277.","DOI":"10.1038\/leu.2016.327"},{"key":"79433","doi-asserted-by":"crossref","unstructured":"Brown PA, Kairalla JA, Hilden JM. FLT3 inhibitor lestaurtinib plus chemotherapy for newly diagnosed KMT2A-rearranged infant acute lymphoblastic leukemia: Children\u2019s Oncology Group trial AALL0631. Leukemia. 2021; 35(5):1279-1290.","DOI":"10.1038\/s41375-021-01177-6"},{"key":"79434","doi-asserted-by":"crossref","unstructured":"Tomizawa D, Miyamura T, Imamura T. A risk-stratified therapy for infants with acute lymphoblastic leukemia: a report from the JPLSG MLL-10 trial. Blood. 2020; 136(16):1813-1823.","DOI":"10.1182\/blood.2019004741"},{"key":"79435","doi-asserted-by":"crossref","unstructured":"van der Sluis IM, de Lorenzo P, Kotecha RS. Blinatumomab added to chemotherapy in infant lymphoblastic leukemia. N Engl J Med. 2023; 388(17):1572-1581.","DOI":"10.1056\/NEJMoa2214171"},{"key":"79436","doi-asserted-by":"crossref","unstructured":"Dreyer ZE, Hilden JM, Jones TL. Intensified chemotherapy without SCT in infant ALL: results from COG P9407 (Cohort 3). Pediatr Blood Cancer. 2015; 62(3):419-426.","DOI":"10.1002\/pbc.25322"},{"key":"79437","doi-asserted-by":"crossref","unstructured":"Koh K, Tomizawa D, Moriya Saito A. Early use of allogeneic hematopoietic stem cell transplantation for infants with MLL gene-rearrangement-positive acute lymphoblastic leukemia. Leukemia. 2015; 29(2):290-296.","DOI":"10.1038\/leu.2014.172"},{"key":"79438","doi-asserted-by":"crossref","unstructured":"Pieters R, den Boer ML, Durian M. Relation between age, immunophenotype and in vitro drug resistance in 395 children with acute lymphoblastic leukemia-implications for treatment of infants. Leukemia. 1998; 12(9):1344-1348.","DOI":"10.1038\/sj.leu.2401129"},{"key":"79439","doi-asserted-by":"crossref","unstructured":"Stutterheim J, van der Sluis IM, de Lorenzo P. Clinical implications of minimal residual disease detection in infants with KMT2A-rearranged acute lymphoblastic leukemia treated on the Interfant-06 protocol. J Clin Oncol. 2021; 39(6):652-662.","DOI":"10.1200\/JCO.20.02333"},{"key":"79440","doi-asserted-by":"crossref","unstructured":"Mann G, Attarbaschi A, Schrappe M. Improved outcome with hematopoietic stem cell transplantation in a poor prognostic subgroup of infants with mixed-lineage-leukemia (MLL)\u2013rearranged acute lymphoblastic leukemia: results from the Interfant-99 study. Blood. 2010; 116(15):2644-2650.","DOI":"10.1182\/blood-2010-03-273532"},{"key":"79441","doi-asserted-by":"crossref","unstructured":"Dreyer ZE, Dinndorf PA, Camitta B. Analysis of the role of hematopoietic stem-cell transplantation in infants with acute lymphoblastic leukemia in first remission and MLL gene rearrangements: a report from the Children\u2019s Oncology Group. J Clin Oncol. 2011; 29(2):214-222.","DOI":"10.1016\/j.yonc.2011.08.027"},{"key":"79442","doi-asserted-by":"crossref","unstructured":"Mironova D, Saraswati CM, Downie P. Late effects in survivors of infant acute lymphoblastic leukaemia-a study of the Australian and New Zealand Children\u2019s Haematology\/ Oncology Group. Blood Cancer J. 2023; 13(1):150.","DOI":"10.1038\/s41408-023-00924-5"},{"key":"79443","doi-asserted-by":"crossref","unstructured":"Gandemer V, Bonneau J, Oudin C. Late effects in survivors of infantile acute leukemia: a study of the L.E.A program. Blood Cancer J. 2017; 7(1):e518.","DOI":"10.1038\/bcj.2016.129"},{"key":"79444","doi-asserted-by":"crossref","unstructured":"Tomizawa D, Koh K, Sato T. Outcome of risk-based therapy for infant acute lymphoblastic leukemia with or without an MLL gene rearrangement, with emphasis on late effects: a final report of two consecutive studies, MLL96 and MLL98, of the Japan Infant Leukemia Study Group. Leukemia. 2007; 21(11):2258-2263.","DOI":"10.1038\/sj.leu.2404903"},{"key":"79445","doi-asserted-by":"crossref","unstructured":"Mulrooney DA, Hyun G, Ness KK. The changing burden of long-term health outcomes in survivors of childhood acute lymphoblastic leukaemia: a retrospective analysis of the St Jude Lifetime Cohort Study. Lancet Haematol. 2019; 6(6):e306-e316.","DOI":"10.1016\/S2352-3026(19)30050-X"},{"key":"79446","doi-asserted-by":"crossref","unstructured":"Kotecha RS, Pieters R, Stutterheim J. KMT2A-rearranged acute lymphoblastic leukaemia. EJC Paediatr Oncol. 2024; 4:100204.","DOI":"10.1016\/j.ejcped.2024.100204"},{"key":"79447","doi-asserted-by":"crossref","unstructured":"Fechina L, Popov A, Tsaur G. Combination of chemotherapy and all-trans retinoic acid for the treatment KMT2A-rearranged infant acute lymphoblastic leukemia. Results of the MLL-Baby trial. Leukemia. 2023; 37(11):2276-2281.","DOI":"10.1038\/s41375-023-02034-4"},{"key":"79448","doi-asserted-by":"crossref","unstructured":"Guest EM, Kairalla JA, Devidas M. Azacitidine as epigenetic priming for chemotherapy is safe and well-tolerated in infants with newly diagnosed KMT2A -rearranged acute lymphoblastic leukemia: Children\u2019s Oncology Group trial AALL15P1. Haematologica. 2024; 109(12):3918-3927.","DOI":"10.3324\/haematol.2024.285158"},{"key":"79449","doi-asserted-by":"crossref","unstructured":"Gruber TA, Huang M, Jeha S. Outcome of infants treated on total therapy for infants with acute lymphoblastic leukemia I: results from a non-randomized multi-center study. Blood. 2023; 142(Supplement 1):823-823.","DOI":"10.1182\/blood-2023-177798"},{"key":"79450","doi-asserted-by":"crossref","unstructured":"Maude SL, Laetsch TW, Buechner J. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N Engl J Med. 2018; 378(5):439-448.","DOI":"10.1056\/NEJMoa1709866"},{"key":"79451","doi-asserted-by":"crossref","unstructured":"Moskop A, Pommert L, Baggott C. Real-world use of tisagenlecleucel in infant acute lymphoblastic leukemia. Blood Adv. 2022; 6(14):4251-4255.","DOI":"10.1182\/bloodadvances.2021006393"},{"key":"79452","doi-asserted-by":"crossref","unstructured":"Ghorashian S, Jacoby E, De Moerloose B. Tisagenlecleucel therapy for relapsed or refractory B-cell acute lymphoblastic leukaemia in infants and children younger than 3 years of age at screening: an international, multicentre, retrospective cohort study. Lancet Haematol. 2022; 9(10):e766-e775.","DOI":"10.1016\/S2352-3026(22)00225-3"},{"key":"79453","doi-asserted-by":"crossref","unstructured":"Hempel G, Relling MV, de Rossi G. Pharmacokinetics of daunorubicin and daunorubicinol in infants with leukemia treated in the Interfant 99 protocol. Pediatr Blood Cancer. 2010; 54(3):355-360.","DOI":"10.1002\/pbc.22266"},{"key":"79454","doi-asserted-by":"crossref","unstructured":"Nijstad AL, Barnett S, Lalmohamed A. Clinical pharmacology of cytotoxic drugs in neonates and infants: providing evidence-based dosing guidance. Eur J Cancer. 2022; 164:137-154.","DOI":"10.1016\/j.ejca.2021.11.001"},{"key":"79455","doi-asserted-by":"crossref","unstructured":"Barnett S, Hellmann F, Parke E. Vincristine dosing, drug exposure and therapeutic drug monitoring in neonate and infant cancer patients. Eur J Cancer. 2022; 164:127-136.","DOI":"10.1016\/j.ejca.2021.09.014"},{"key":"79456","doi-asserted-by":"crossref","unstructured":"Lonnerholm G, Valsecchi MG, De Lorenzo P. Pharmacokinetics of high-dose methotrexate in infants treated for acute lymphoblastic leukemia. Pediatr Blood Cancer. 2009; 52(5):596-601.","DOI":"10.1002\/pbc.21925"},{"key":"79457","doi-asserted-by":"crossref","unstructured":"Nijstad AL, Chu W-Y, de Vos-Kerkhof E. A population pharmacokinetic modelling approach to unravel the complex pharmacokinetics of vincristine in children. Pharm Res. 2022; 39(10):2487-2495.","DOI":"10.1007\/s11095-022-03364-1"},{"key":"79458","doi-asserted-by":"crossref","unstructured":"Kearns GL, Abdel-Rahman SM, Alander SW, Blowey DL, Leeder JS, Kauffman RE. Developmental pharmacology--drug disposition, action, and therapy in infants and children. N Engl J Med. 2003; 349(12):1157-1167.","DOI":"10.1056\/NEJMra035092"},{"key":"79459","doi-asserted-by":"crossref","unstructured":"Lim SY, Pettit RS. Pharmacokinetic considerations in pediatric pharmacotherapy. Am J Health Syst Pharm. 2019; 76(19):1472-1480.","DOI":"10.1093\/ajhp\/zxz161"},{"key":"79460","doi-asserted-by":"crossref","unstructured":"Lee CM, Zane NR, Veal G, Thakker DR. Physiologically based pharmacokinetic models for adults and children reveal a role of intracellular tubulin binding in vincristine disposition. CPT Pharmacometrics Syst Pharmacol. 2019; 8(10):759-768.","DOI":"10.1002\/psp4.12453"},{"key":"79461","doi-asserted-by":"crossref","unstructured":"Brigitha LJ, Mondelaers V, Liu Y. Pharmacokinetics of PEGasparaginase in infants with acute lymphoblastic leukemia. Pharm Res. 2024; 41(4):711-720.","DOI":"10.1007\/s11095-024-03693-3"},{"key":"79462","doi-asserted-by":"crossref","unstructured":"Queudeville M, Stein AS, Locatelli F. Low leukemia burden improves blinatumomab efficacy in patients with relapsed\/ refractory B-cell acute lymphoblastic leukemia. Cancer. 2023; 129(9):1384-1393.","DOI":"10.1002\/cncr.34667"},{"key":"79463","doi-asserted-by":"crossref","unstructured":"Essa MF, Abdellatif R, Elimam N. Outcomes of blinatumomab based therapy in children with relapsed, persistent, or refractory acute lymphoblastic leukemia: a multicenter study focusing on predictors of response and post-treatment immunoglobulin production. Pediatr Hematol Oncol. 2022; 39(7):613-628.","DOI":"10.1080\/08880018.2022.2049936"},{"key":"79464","doi-asserted-by":"crossref","unstructured":"Szymanska B, Wilczynska-Kalak U, Kang MH. Pharmacokinetic modeling of an induction regimen for in vivo combined testing of novel drugs against pediatric acute lymphoblastic leukemia xenografts. PLoS One. 2012; 7(3):e33894.","DOI":"10.1371\/journal.pone.0033894"},{"key":"79465","doi-asserted-by":"crossref","unstructured":"Jones L, Richmond J, Evans K. Bioluminescence imaging enhances analysis of drug responses in a patient-derived xenograft model of pediatric ALL. Clin Cancer Res. 2017; 23(14):3744-3755.","DOI":"10.1158\/1078-0432.CCR-16-2392"},{"key":"79466","doi-asserted-by":"crossref","unstructured":"Schneider P, Crump NT, Arentsen-Peters S. Modelling acquired resistance to DOT1L inhibition exhibits the adaptive potential of KMT2A-rearranged acute lymphoblastic leukemia. Exp Hematol Oncol. 2023; 12(1):81.","DOI":"10.1186\/s40164-023-00445-8"},{"key":"79467","doi-asserted-by":"crossref","unstructured":"Adriaanse FRS, Schneider P, Arentsen-Peters S. Distinct responses to menin inhibition and synergy with DOT1L inhibition in KMT2A-rearranged acute lymphoblastic and myeloid leukemia. Int J Mol Sci. 2024; 25(11):6020.","DOI":"10.3390\/ijms25116020"},{"key":"79468","doi-asserted-by":"crossref","unstructured":"Stein EM, Garcia-Manero G, Rizzieri DA. The DOT1L inhibitor pinometostat reduces H3K79 methylation and has modest clinical activity in adult acute leukemia. Blood. 2018; 131(24):2661-2669.","DOI":"10.1182\/blood-2017-12-818948"},{"key":"79469","doi-asserted-by":"crossref","unstructured":"Perner F, Stein EM, Wenge DV. MEN1 mutations mediate clinical resistance to menin inhibition. Nature. 2023; 615(7954):913-919.","DOI":"10.1038\/s41586-023-05755-9"},{"key":"79470","doi-asserted-by":"crossref","unstructured":"Perner F, Armstrong SA. Targeting chromatin complexes in myeloid malignancies and beyond: from basic mechanisms to clinical innovation. Cells. 2020; 9(12):2721.","DOI":"10.3390\/cells9122721"},{"key":"79471","doi-asserted-by":"crossref","unstructured":"Gilan O, Lam EY, Becher I. Functional interdependence of BRD4 and DOT1L in MLL leukemia. Nat Struct Mol Biol. 2016; 23(7):673-681.","DOI":"10.1038\/nsmb.3249"},{"key":"79472","doi-asserted-by":"crossref","unstructured":"Bardini M, Trentin L, Rizzo F. Antileukemic efficacy of BET Inhibitor in a preclinical mouse model of MLL-AF4(+) infant ALL. Mol Cancer Ther. 2018; 17(8):1705-1716.","DOI":"10.1158\/1535-7163.MCT-17-1123"},{"key":"79473","doi-asserted-by":"crossref","unstructured":"Li X, Song Y. Structure, function and inhibition of critical protein-protein interactions involving mixed lineage leukemia 1 and its fusion oncoproteins. J Hematol Oncol. 2021; 14(1):56.","DOI":"10.1186\/s13045-021-01057-7"},{"key":"79474","doi-asserted-by":"crossref","unstructured":"Erb MA, Scott TG, Li BE. Transcription control by the ENL YEATS domain in acute leukaemia. Nature. 2017; 543(7644):270-274.","DOI":"10.1038\/nature21688"},{"key":"79475","doi-asserted-by":"crossref","unstructured":"Ma XR, Xu L, Xu S. Discovery of selective small-molecule inhibitors for the ENL YEATS domain. J Med Chem. 2021; 64(15):10997-11013.","DOI":"10.1021\/acs.jmedchem.1c00367"},{"key":"79476","doi-asserted-by":"crossref","unstructured":"Liu Y, Li Q, Alikarami F. Small-molecule inhibition of the acyl-lysine reader ENL as a strategy against acute myeloid leukemia. Cancer Discov. 2022; 12(11):2684-2709.","DOI":"10.1158\/2159-8290.CD-21-1307"},{"key":"79477","doi-asserted-by":"crossref","unstructured":"Garnar-Wortzel L, Bishop TR, Kitamura S. Chemical inhibition of ENL\/AF9 YEATS domains in acute leukemia. ACS Cent Sci. 2021; 7(5):815-830.","DOI":"10.1021\/acscentsci.0c01550"},{"key":"79478","doi-asserted-by":"crossref","unstructured":"Driessen EM, de Lorenzo P, Campbell M. Outcome of relapsed infant acute lymphoblastic leukemia treated on the Interfant-99 protocol. Leukemia. 2016; 30(5):1184-1187.","DOI":"10.1038\/leu.2015.246"},{"key":"79479","doi-asserted-by":"crossref","unstructured":"Roberts KG, Mullighan CG. Genomics in acute lymphoblastic leukaemia: insights and treatment implications. Nat Rev Clin Oncol. 2015; 12(6):344-357.","DOI":"10.1038\/nrclinonc.2015.38"},{"key":"79480","doi-asserted-by":"crossref","unstructured":"Hong SP, Chan TE, Lombardo Y. Single-cell transcriptomics reveals multi-step adaptations to endocrine therapy. Nat Commun. 2019; 10(1):3840.","DOI":"10.1038\/s41467-019-11721-9"},{"key":"79481","doi-asserted-by":"crossref","unstructured":"Good Z, Sarno J, Jager A. Single-cell developmental classification of B cell precursor acute lymphoblastic leukemia at diagnosis reveals predictors of relapse. Nat Med. 2018; 24(4):474-483.","DOI":"10.1038\/nm.4505"},{"key":"79482","doi-asserted-by":"crossref","unstructured":"Shlush LI, Mitchell A, Heisler L. Tracing the origins of relapse in acute myeloid leukaemia to stem cells. Nature. 2017; 547(7661):104-108.","DOI":"10.1038\/nature22993"},{"key":"79483","doi-asserted-by":"crossref","unstructured":"Batlle E, Clevers H. Cancer stem cells revisited. Nat Med. 2017; 23(10):1124-1134.","DOI":"10.1038\/nm.4409"},{"key":"79484","doi-asserted-by":"crossref","unstructured":"Dick JE. Stem cell concepts renew cancer research. Blood. 2008; 112(13):4793-4807.","DOI":"10.1182\/blood-2008-08-077941"},{"key":"79485","doi-asserted-by":"crossref","unstructured":"Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011; 144(5):646-674.","DOI":"10.1016\/j.cell.2011.02.013"},{"key":"79486","doi-asserted-by":"crossref","unstructured":"Bardini M, Woll PS, Corral L. Clonal variegation and dynamic competition of leukemia-initiating cells in infant acute lymphoblastic leukemia with MLL rearrangement. Leukemia. 2015; 29(1):38-50.","DOI":"10.1038\/leu.2014.154"},{"key":"79487","doi-asserted-by":"crossref","unstructured":"Andersson AK, Ma J, Wang J. The landscape of somatic mutations in infant MLL-rearranged acute lymphoblastic leukemias. Nat Genet. 2015; 47(4):330-337.","DOI":"10.1038\/ng.3230"},{"key":"79488","doi-asserted-by":"crossref","unstructured":"Agraz-Doblas A, Bueno C, Bashford-Rogers R. Unraveling the cellular origin and clinical prognostic markers of infant B-cell acute lymphoblastic leukemia using genome-wide analysis. Haematologica. 2019; 104(6):1176-1188.","DOI":"10.3324\/haematol.2018.206375"},{"key":"79489","doi-asserted-by":"crossref","unstructured":"Tejedor JR, Bueno C, Vinyoles M. Integrative methylome-transcriptome analysis unravels cancer cell vulnerabilities in infant MLL-rearranged B cell acute lymphoblastic leukemia. J Clin Invest. 2021; 131(13):e138833.","DOI":"10.1172\/JCI138833"},{"key":"79490","doi-asserted-by":"crossref","unstructured":"Candelli T, Schneider P, Garrido Castro P. Identification and characterization of relapse-initiating cells in MLL-rearranged infant ALL by single-cell transcriptomics. Leukemia. 2022; 36(1):58-67.","DOI":"10.1038\/s41375-021-01341-y"},{"key":"79491","doi-asserted-by":"crossref","unstructured":"Chen C, Yu W, Alikarami F. Single-cell multiomics reveals increased plasticity, resistant populations, and stem-cell-like blasts in KMT2A-rearranged leukemia. Blood. 2022; 139(14):2198-2211.","DOI":"10.1182\/blood.2021013442"},{"key":"79492","doi-asserted-by":"crossref","unstructured":"Kurzer JH, Weinberg OK. To B- or not to B-: a review of lineage switched acute leukemia. Int J Lab Hematol. 2022; 44(Suppl 1):64-70.","DOI":"10.1111\/ijlh.13923"},{"key":"79493","doi-asserted-by":"crossref","unstructured":"Dorantes-Acosta E, Pelayo R. Lineage switching in acute leukemias: a consequence of stem cell plasticity?. Bone Marrow Res. 2012; 2012:406796.","DOI":"10.1155\/2012\/406796"},{"key":"79494","doi-asserted-by":"crossref","unstructured":"Tirtakusuma R, Szoltysek K, Milne P. Epigenetic regulator genes direct lineage switching in MLL\/AF4 leukemia. Blood. 2022; 140(17):1875-1890.","DOI":"10.1182\/blood.2021015036"},{"key":"79495","doi-asserted-by":"crossref","unstructured":"Gardner R, Wu D, Cherian S. Acquisition of a CD19-negative myeloid phenotype allows immune escape of MLL-rearranged B-ALL from CD19 CAR-T-cell therapy. Blood. 2016; 127(20):2406-2410.","DOI":"10.1182\/blood-2015-08-665547"},{"key":"79496","doi-asserted-by":"crossref","unstructured":"Lamble AJ, Myers RM, Taraseviciute A. Preinfusion factors impacting relapse immunophenotype following CD19 CAR T cells. Blood Adv. 2023; 7(4):575-585.","DOI":"10.1182\/bloodadvances.2022007423"},{"key":"79497","doi-asserted-by":"crossref","unstructured":"Bataller A, Abuasab T, McCall D. Myeloid lineage switch in KMT2A-rearranged acute lymphoblastic leukemia treated with lymphoid lineage-directed therapies. Haematologica. 2024; 109(1):293-297.","DOI":"10.3324\/haematol.2023.283705"},{"key":"79498","doi-asserted-by":"crossref","unstructured":"Tasian SK. TCF3::HLF acute lymphoblastic leukemia: still challenging to cure thirty years later. Haematologica. 2023; 108(7):1713-1714.","DOI":"10.3324\/haematol.2023.283148"},{"key":"79499","doi-asserted-by":"crossref","unstructured":"Janssens DH, Duran M, Otto DJ. MLL oncoprotein levels influence leukemia lineage identities. Nat Commun. 2024; 15(1):9341.","DOI":"10.1038\/s41467-024-53399-8"},{"key":"79500","doi-asserted-by":"crossref","unstructured":"Thastrup M, Duguid A, Mirian C, Schmiegelow K, Halsey C. Central nervous system involvement in childhood acute lymphoblastic leukemia: challenges and solutions. Leukemia. 2022; 36(12):2751-2768.","DOI":"10.1038\/s41375-022-01714-x"},{"key":"79501","doi-asserted-by":"crossref","unstructured":"Tomizawa D, Koh K, Sato T. Outcome of risk-based therapy for infant acute lymphoblastic leukemia with or without an MLL gene rearrangement, with emphasis on late effects: a final report of two consecutive studies, MLL96 and MLL98, of the Japan Infant Leukemia Study Group. Leukemia. 2007; 21(11):2258-2263.","DOI":"10.1038\/sj.leu.2404903"},{"key":"79502","doi-asserted-by":"crossref","unstructured":"Popov A, Tsaur G, Permikin Z. Incidence and prognostic value of central nervous system involvement in infants with B-cell precursor acute lymphoblastic leukemia treated according to the MLL-Baby protocol. Pediatr Blood Cancer. 2022; 69(9):e29860.","DOI":"10.1002\/pbc.29860"},{"key":"79503","doi-asserted-by":"crossref","unstructured":"Salzer WL, Burke MJ, Devidas M. Impact of intrathecal triple therapy versus intrathecal methotrexate on disease-free survival for high-risk B-lymphoblastic leukemia: Children\u2019s Oncology Group study AALL1131. J Clin Oncol. 2020; 38(23):2628-2638.","DOI":"10.1200\/JCO.19.02892"},{"key":"79504","doi-asserted-by":"crossref","unstructured":"Pieters R, de Groot-Kruseman H, Fiocco M. Improved outcome for ALL by prolonging therapy for IKZF1 deletion and decreasing therapy for other risk groups. J Clin Oncol. 2023; 41(25):4130-4142.","DOI":"10.1200\/JCO.22.02705"},{"key":"79505","doi-asserted-by":"crossref","unstructured":"Gupta S, Rau RE, Kairalla JA. Blinatumomab in standardrisk B-cell acute lymphoblastic leukemia in children. N Engl J Med. 2025; 392(9):875-891.","DOI":"10.1056\/NEJMoa2411680"},{"key":"79506","doi-asserted-by":"crossref","unstructured":"Matloub Y, Lindemulder S, Gaynon PS. Intrathecal triple therapy decreases central nervous system relapse but fails to improve event-free survival when compared with intrathecal methotrexate: results of the Children\u2019s Cancer Group (CCG) 1952 study for standard-risk acute lymphoblastic leukemia, reported by the Children\u2019s Oncology Group. Blood. 2006; 108(4):1165-1173.","DOI":"10.1182\/blood-2005-12-011809"},{"key":"79507","doi-asserted-by":"crossref","unstructured":"Leahy AB, Newman H, Li Y. CD19-targeted chimeric antigen receptor T-cell therapy for CNS relapsed or refractory acute lymphocytic leukaemia: a post-hoc analysis of pooled data from five clinical trials. Lancet Haematol. 2021; 8(10):e711-e722.","DOI":"10.1016\/S2352-3026(21)00238-6"},{"key":"79508","doi-asserted-by":"crossref","unstructured":"Jacoby E, Ghorashian S, Vormoor B. CD19 CAR T-cells for pediatric relapsed acute lymphoblastic leukemia with active CNS involvement: a retrospective international study. Leukemia. 2022; 36(6):1525-1532.","DOI":"10.1038\/s41375-022-01546-9"},{"key":"79509","doi-asserted-by":"crossref","unstructured":"Prieto C, Lopez-Millan B, Roca-Ho H. NG2 antigen is involved in leukemia invasiveness and central nervous system infiltration in MLL-rearranged infant B-ALL. Leukemia. 2018; 32(3):633-644.","DOI":"10.1038\/leu.2017.294"},{"key":"79510","doi-asserted-by":"crossref","unstructured":"Lopez-Millan B, Sanchez-Martinez D, Roca-Ho H. NG2 antigen is a therapeutic target for MLL-rearranged B-cell acute lymphoblastic leukemia. Leukemia. 2019; 33(7):1557-1569.","DOI":"10.1038\/s41375-018-0353-0"}],"container-title":["Haematologica"],"original-title":[],"link":[{"URL":"https:\/\/haematologica.org\/article\/download\/12017\/78276","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/12017\/78777","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/12017\/78276","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:08:34Z","timestamp":1794046114000},"score":1,"resource":{"primary":{"URL":"https:\/\/haematologica.org\/article\/view\/12017"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,10]]},"references-count":88,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2025,9,1]]}},"URL":"https:\/\/doi.org\/10.3324\/haematol.2024.285642","relation":{},"ISSN":["1592-8721","0390-6078"],"issn-type":[{"value":"1592-8721","type":"electronic"},{"value":"0390-6078","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4,10]]}}}